Interestingly, nine out of 14 patients who achieved CR/CRi cleared the mutation, suggesting that not only does monotherapy with ivosidenib produce durable remissions for newly diagnosed AML, but it may also alter the biology of IDH1 positive AML itself [3]. Here, IDH1 is linked to acute myeloid leukemia.